scispace - formally typeset
E

Eric Eveno

Researcher at Centre national de la recherche scientifique

Publications -  31
Citations -  2286

Eric Eveno is an academic researcher from Centre national de la recherche scientifique. The author has contributed to research in topics: Xeroderma pigmentosum & DNA repair. The author has an hindex of 20, co-authored 30 publications receiving 2182 citations. Previous affiliations of Eric Eveno include Shanghai Jiao Tong University & Pierre-and-Marie-Curie University.

Papers
More filters
Journal ArticleDOI

Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces

TL;DR: The reliability of conventional methods for RNA quality assessment including UV spectroscopy and 28S:18S area ratios are evaluated, and their inconsistency is demonstrated, and two new freely available classifiers are used, the Degradometer and RIN systems, to produce user-independent RNA quality metrics, based on analysis of microcapillary electrophoresis traces.
Journal ArticleDOI

Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones

Tadashi Imanishi, +167 more
- 20 Apr 2004 - 
TL;DR: The H-InvDB as discussed by the authors is a database of 41,118 full-length cDNAs that capture the gene transcripts as complete functional cassettes, providing an unequivocal report of structural and functional diversity at the gene level.
Journal Article

A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy.

TL;DR: Findings define a third TTD complementation group, extend the clinical heterogeneity associated with XP-B, stress the exclusive relationship between TTD and mutations in subunits of repair/transcription factor TFIIH, and strongly support the concept of "transcription syndromes."
Journal ArticleDOI

Deciphering cellular states of innate tumor drug responses.

TL;DR: Molecular interaction networks are described that provide a solid foundation on which to anchor working hypotheses about mechanisms underlying in vivo innate tumor drug responses, and represent a starting point from which by-pass chemotherapy schemes may be developed for critical therapeutic intervention in CRC patients.